Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

INTRODUCTION: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Dement (N Y)
Autors principals: Schwarz, Adam J., Sundell, Karen L., Charil, Arnaud, Case, Michael G., Jaeger, Ralf K., Scott, David, Bracoud, Luc, Oh, Joonmi, Suhy, Joyce, Pontecorvo, Michael J., Dickerson, Bradford C., Siemers, Eric R.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Featured Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675941/
https://ncbi.nlm.nih.gov/pubmed/31388559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2019.05.007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars